How a Prostate Biopsy Is Performed and What to Expect

A prostate biopsy involves a doctor using a thin, spring-loaded needle to collect small tissue samples from the prostate gland, which are then examined under a microscope for signs of cancer. The procedure typically takes 15 to 30 minutes, is usually done as an outpatient visit, and most men go home the same day. While the idea of it tends to generate more anxiety than the procedure itself warrants, knowing the specific steps, the sensations involved, and what the recovery looks like can take much of the uncertainty out of the experience.

Why Your Doctor Recommends a Biopsy

A biopsy is not the first step. It follows a chain of earlier findings that suggest cancer could be present. The main triggers are a prostate-specific antigen (PSA) blood level above 4 ng/mL alongside other risk factors, an abnormal digital rectal exam where the doctor feels a hard or irregular area, or a suspicious lesion spotted on a multiparametric MRI scan that scores 4 or 5 on the PI-RADS scale, a standardized rating system radiologists use to grade how likely a prostate abnormality is to be cancer.¹ Not every elevated PSA leads to a biopsy. Your urologist weighs your age, family history, ethnicity, and whether your PSA has been rising over time before recommending the procedure.

The MRI Step That Often Comes First

Many urology practices now order a multiparametric MRI of the prostate before any needles are involved. The scan produces detailed images that highlight areas of concern, each scored on the PI-RADS scale from 1 (very unlikely cancer) to 5 (very likely cancer). That score shapes what happens next. For high-scoring lesions (PI-RADS 5), targeted biopsy aimed directly at the suspicious spot catches nearly all significant cancers on its own. For mid-range scores (PI-RADS 3 and 4), combining targeted sampling with a broader systematic sweep across the gland picks up more cancers than either method alone.² MRI also helps predict whether a biopsy sample might underestimate the cancer’s aggressiveness, which matters for treatment planning down the line.³

If you are told a biopsy is necessary without a prior MRI, that is not automatically a red flag. Some clinical situations, like a very high PSA or a clearly abnormal exam, may warrant proceeding directly. But if the option exists, having the MRI first allows for more precise needle placement and often fewer unnecessary biopsies.

Transrectal Versus Transperineal: Two Routes to the Same Gland

The needle can reach the prostate from two directions. In a transrectal biopsy, the ultrasound probe and needle guide go through the rectum wall. In a transperineal biopsy, the needle enters through the perineum, the small patch of skin between the scrotum and the anus. Both approaches effectively sample the prostate, but they differ meaningfully when it comes to infection risk.

Because the transrectal route passes the needle through the bowel wall, bacteria can hitch a ride into the bloodstream or urinary tract. Infectious complications after transrectal biopsy, depending on the antibiotic regimen used, have been reported in roughly 0.1% to 7% of cases, with sepsis rates between 0.3% and 3.1%.⁴ The transperineal approach bypasses the rectum entirely. A large randomized trial found zero infections in the transperineal group compared with a 1.6% infection rate in the transrectal group.⁵ A meta-analysis of ten randomized trials confirmed the pattern, finding the transperineal route reduced hospitalization for infectious complications by about 77%.⁶

This safety advantage has pushed many practices to switch to the transperineal approach, and several major guidelines now favor it. Still, transrectal biopsies remain common, particularly where equipment or training for the perineal route is not yet available. If you are offered a transrectal biopsy, antibiotic prophylaxis and sometimes rectal preparation are used to keep infection risk low. Some centers use targeted antibiotic strategies based on rectal swab cultures, while others use broader-spectrum prophylaxis such as third-generation cephalosporins.⁷

Systematic, Targeted, or Both

Beyond the route, there is also the question of how the tissue samples are chosen. A systematic biopsy follows a standardized template, typically collecting 10 to 12 cores from evenly distributed locations across the gland, regardless of what imaging shows. A targeted biopsy uses the MRI data, fused in real time with the ultrasound image, to guide needles directly into suspicious-looking areas. Most modern practices combine both.

Head-to-head comparisons show that MRI-targeted biopsy finds cancer in a higher share of patients and catches it in a higher percentage of individual cores than systematic biopsy alone.⁸ The advantage is most pronounced in men with PI-RADS 4 and 5 lesions, where fusion-targeted biopsy detected clinically significant cancer at a rate of 31% compared with about 25% for systematic biopsy alone.⁹ The combined approach matters because each method catches some cancers the other misses. One large study found fusion biopsy alone detected significant cancer in about 29% of patients while systematic biopsy caught it in 26%, and combining them improved the overall yield beyond either individually.¹⁰

What Actually Happens During the Procedure

If you are having a transrectal biopsy, you lie on your side with your knees drawn up. The doctor inserts a thin ultrasound probe into the rectum. The ultrasound image guides a spring-loaded biopsy gun that fires a thin needle through the rectal wall into the prostate. Each core takes less than a second to collect. You hear a click and feel a brief, sharp pinch. This is repeated for each sample, typically 12 to 16 times over 15 to 20 minutes.

For a transperineal biopsy, you usually lie on your back with your legs in stirrups. The ultrasound probe goes into the rectum for imaging, but the biopsy needle enters through the perineal skin instead. A small area of skin is numbed with local anesthetic first. Some centers use a grid template held against the perineum to guide needle placement; others use freehand technique with real-time ultrasound tracking. Newer systems track the needle path in three dimensions and record each core’s exact position, which is useful if a repeat biopsy is ever needed.

When MRI-fusion guidance is used, software overlays the previously acquired MRI images onto the live ultrasound feed. The doctor can then steer the needle toward the exact spot flagged on the MRI. The fusion system typically tracks prostate motion so the overlay stays aligned even if you shift slightly during the procedure.

How Pain Is Managed

Most prostate biopsies are performed under local anesthesia, not general. For transrectal procedures, the standard is a periprostatic nerve block, where the doctor injects lidocaine near the nerve bundles at the base of the prostate. This reliably cuts pain roughly in half compared with using only topical anesthetic gel. In one randomized trial, men who received a nerve block rated their pain around 1.9 on a 10-point scale, compared with 3.3 for those without it.¹¹ Men who had experienced a prior biopsy without nerve block and then received one rated the difference as dramatic, with scores dropping from about 4.6 to 1.7.

There is also evidence that where the block is placed matters. Injecting anesthetic at both the base and the apex of the prostate provides better pain control than injecting only at the base, particularly during sampling of the front part of the gland.¹² Adding sedation or intravenous pain medication brought pain scores even lower in a randomized comparison, with average scores near 1 on a 10-point scale.¹³ For transperineal biopsies, local anesthetic injected into the perineal skin plus a nerve block is the most common approach, though some centers offer light sedation.

The honest picture: the procedure is uncomfortable but manageable for most men. The ultrasound probe in the rectum produces a sensation of pressure. Each needle fire causes a quick, sharp sting. Most men describe the anticipation as worse than the event itself.

Common Side Effects Afterward

Some degree of bleeding is nearly universal and generally harmless. You can expect blood in the urine for a few days, occasionally up to a couple of weeks. Blood in the stool (mostly after transrectal biopsy) is usually minor and clears within a day or two. The most persistent side effect is blood in the semen. A prospective study found that about 90% of men who could ejaculate after a transrectal biopsy noticed blood-tinged semen, lasting an average of four weeks.¹⁴ Systematic reviews confirm that these bleeding symptoms, while common, are typically mild and self-limiting regardless of biopsy approach.¹⁵ Severe rectal bleeding is uncommon.¹⁶

You should contact your doctor if bleeding is heavy, does not improve over several days, or is accompanied by fever, chills, or difficulty urinating. Some temporary urinary symptoms like increased frequency or mild burning are common and usually resolve within a few days. Erectile function and urinary control are not meaningfully affected by the biopsy itself.¹⁷

Infection Risk in Context

Infection is the complication that gets the most clinical attention, and the one where the choice of biopsy route makes the biggest practical difference. After transrectal biopsy, sepsis rates depend heavily on local resistance patterns. At one tertiary center, the urosepsis rate reached 9.4%, with the majority of infections caused by antibiotic-resistant E. coli.¹⁸ That figure is at the high end. Across larger datasets, infectious complication rates after transrectal biopsy generally range from under 1% to about 7%, and the trend has been toward stricter antibiotic protocols to bring those numbers down.⁴

For transperineal biopsy, infection is rare enough that some centers have dropped routine antibiotic prophylaxis entirely, though this remains debated. The key warning signs to watch for in the days after any prostate biopsy are fever above 100.4°F (38°C), shaking chills, inability to urinate, or worsening pelvic pain. These need urgent medical attention.

Understanding Your Pathology Results

Results typically come back within one to two weeks. Each tissue core is examined by a pathologist who determines whether cancer cells are present and, if so, how abnormal they look. The grading system you will encounter is the ISUP Grade Group system, which runs from 1 to 5. Grade Group 1 represents the least aggressive cancers, while Grade Group 5 is the most aggressive. This grading system was adopted internationally because it is more intuitive for patients than the older Gleason scoring system, where a score of 6 sounded alarming even though it represented the lowest-grade cancer.¹⁹

Your report will also note how many cores were positive, what percentage of each core contained cancer, and whether cancer was present on one or both sides of the gland. These details matter as much as the grade itself. A single core with a small amount of Grade Group 1 cancer is a very different situation from twelve cores with extensive Grade Group 4.

When the Result Is Not a Clear Yes or No

Not every biopsy comes back as “cancer” or “no cancer.” Two findings fall into a gray zone. Atypical small acinar proliferation (ASAP) means the pathologist saw clusters of cells that look suspicious but were too few or too ambiguous to diagnose definitively as cancer. High-grade prostatic intraepithelial neoplasia (HGPIN) describes cells that look abnormal under the microscope but have not invaded surrounding tissue. Both findings signal a higher-than-average chance that cancer exists somewhere in the prostate, whether in an area the biopsy missed or as a very early process.

In one large study, cancer was found on a subsequent biopsy in about 46% of men initially diagnosed with ASAP and 37% of those with HGPIN alone. When both were present, cancer was found in roughly 68%. The rate of clinically significant cancer, however, was similar across all three groups, around 10%.²⁰ Research also suggests that the clinical meaning of these findings depends on how the biopsy was done. ASAP or HGPIN found during a standard systematic biopsy may be more likely to indicate a larger, missed cancer elsewhere in the gland, while the same findings on MRI-targeted biopsy tend to reflect a more indolent process.²¹ If you receive one of these results, your urologist will typically recommend a repeat biopsy or closer surveillance rather than immediate treatment.

The Emotional Side of Biopsy

The psychological burden of a prostate biopsy is real and tends to be underappreciated by the medical system. Anxiety peaks before the biopsy, while you are waiting and uncertain, and it drops significantly once results arrive.¹⁷ But “results arrive” does not always mean relief. In a study of over 300 men, about half reported significant biopsy-related distress. The odds of distress were roughly three times higher in men whose results showed cancer and more than double in men who got an indeterminate result compared to those with a negative result. Men who were generally prone to health anxiety had even higher distress regardless of what the biopsy showed.²²

Men who have had a previous biopsy tend to feel more distressed when told they need another one, carrying the memory of the earlier procedure forward. If you are someone who tends toward health-related worry, it is worth flagging this with your doctor. Some practices offer structured support, from pre-biopsy counseling to clear timelines for when results will arrive, all of which help.

Urine-Based Tests and Whether They Can Replace Biopsy

You may have heard about blood or urine tests marketed as alternatives to biopsy. The most studied urine-based biomarker is PCA3, a molecule overproduced by prostate cancer cells. At the most commonly used cutoff score, PCA3 achieves a sensitivity of about 58% and a specificity of about 72% for detecting prostate cancer, which outperforms PSA alone but is far from definitive.²³ In practical terms, these tests can help decide whether a biopsy is worth doing, particularly in men sitting in the gray zone of modestly elevated PSA, but they cannot replace the tissue-level information a biopsy provides. A pathologist looking at cells under a microscope remains the only way to diagnose prostate cancer and determine its grade.

Disparities in Who Gets MRI-Guided Biopsy

Access to pre-biopsy MRI and MRI-fusion biopsy is not evenly distributed. A population-based study found that Black men were about 20% less likely than white men to undergo prostate MRI as recently as 2019, a gap that had narrowed from 43% a few years earlier but remained significant.²⁴ Rural residents were about 35% less likely to receive MRI than those in urban areas, and income, education, and insurance status all played a role. A separate analysis of over 94,000 cases found similarly low MRI utilization among Black and Hispanic patients compared with white patients.²⁵

The consequences are not just theoretical. At one institution, only about 23% of Black men underwent MRI-fusion biopsy compared with roughly 52% of white men, even after adjusting for age, PSA level, and insurance. Black race was a significant independent predictor of not receiving the more accurate biopsy method.²⁶ Given that Black men already face higher prostate cancer incidence and mortality, unequal access to the most accurate diagnostic tools is a compounding problem. If you are in a group that faces these disparities, advocating for MRI-guided biopsy when it is clinically appropriate is worth the conversation with your urologist.

How Biopsy Technique Has Changed

The modern prostate biopsy looks almost nothing like its predecessor from 30 years ago. Earlier biopsies were aimed at palpable lumps felt on rectal exam and relied on relatively crude needle placement. The introduction of transrectal ultrasound in the 1980s and the widespread adoption of PSA screening shifted the goal from confirming obvious disease to detecting early, non-palpable cancers. That shift led to the systematic 12-core template biopsy that became standard. More recently, the trend has moved toward image-guided targeted biopsies designed to extract the most cancer information from the fewest possible cores.²⁷ The trajectory is toward fewer needle passes, better accuracy, and less reliance on sampling blindly across the gland. For men undergoing biopsy today, this means a more precise procedure with a better chance of catching significant disease while avoiding unnecessary detection of slow-growing cancers that would never cause harm.